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ABSTRACT 
The Mycobacterium tuberculosis twin-arginine translocation pathway. (May 2014) 
 
Meenakshi Manivannan 
Department of Molecular and Cellular Medicine 
Texas A&M Health Science Center 
 
Research Advisor: Dr. Siegfried Musser 
Department of Molecular and Cellular Medicine  
 
Mycobacterium tuberculosis (MTb) is the causative agent of tuberculosis. It is difficult to study 
biochemically because of its slow growth rate and its pathogenicity, which requires BSL3 
conditions. The twin-arginine translocation (Tat) pathway of MTb is essential for its growth and 
virulence1. The Musser lab has worked on the Escherichia coli Tat system for over 12 years and 
has developed numerous biochemical and biophysical assays. This expertise will now be applied 
toward the MTb Tat machinery. Our hypothesis is that the Tat system is a good drug target 
because it is essential for the growth and function of MTb. The proposed work seeks to express 
the MTb Tat proteins in E. coli to more easily functionally study the MTb Tat machinery. The 
major outcome of a successful project will be a functional in vitro MTb Tat transport assay that 
can be used for biochemical studies, and, in particular, for drug development.  
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NOMENCLATURE 
  
EDTA 
LB 
MTb 
IMV 
PCR 
SDS 
Ethylenediaminetetraacetic acid 
 
Luria-Bertani 
Mycobacterium tuberculosis 
Inverted Membrane Vesicles 
Polymerase Chain Reaction 
Sodium dodecyl sulfate 
TB Tuberculosis 
Tat Twin-arginine translocation 
 
  
5	  
	  
CHAPTER I 
INTRODUCTION 
 
Tuberculosis: an epidemic 
Tuberculosis is an airborne disease that predominantly affects the human respiratory system. 
About one-third of the world's population is infected with tuberculosis and in 2011, 9 million 
people became sick with tuberculosis worldwide (10,500 of which were reported in the United 
States)2. Most of the individuals afflicted by this disease reside in third world countries3. The 
Tuberculosis-causing bacteria Mycobacterium tuberculosis primarily targets the lungs; however, 
it is capable of spreading to the kidney, spine and even the brain. There are two primary types of 
tuberculosis-latent tuberculosis and tuberculosis disease. In latent tuberculosis, the tuberculosis 
bacteria live in the body but do not cause the individual to become sick because the individual’s 
immune system is capable of fighting off and preventing the bacteria from multiplying. The 
individual, at any time, can lose the ability to fight off the bacteria, causing full-blown 
tuberculosis disease. Tuberculosis disease is the state during which the individual’s body cannot 
control the growth of the multiplying tuberculosis bacteria. Individuals afflicted with this 
condition are typically infectious4. 
 
There has been an alarming increase in multi-drug resistance (MDR) strains of tuberculosis. 
Currently, MDR is defined as strains that are resistant to two out of the four most effective drugs 
(isoniazid and rifampin). Within the category of MDR strains, there is a subcategory known as 
extensively drug resistant (XDR) strains. These strains are not only resistant to isoniazid and 
rifampin, but also to fluoroquine and one out of three injectable anti-tuberculosis drugs such as 
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kanamycin, capreomycin and amikacin.  3.7% of individuals who are diagnosed with 
tuberculosis and 20% who have already been diagnosed with tuberculosis have MDR 
tuberculosis, which translates to about 630,000 individuals. Of all the individuals with MDR 
tuberculosis, approximately 9% have XDR tuberculosis. The alternatives for those with MDR 
strains are limited and are often harmful and require extensive procedures such as sputum culture 
conversion with 5 or 6 drugs. These treatment methods are much more expensive and time 
consuming than those with first-line drugs5. 
 
In recent decades, there has been a global decline in spending for research and the development 
of drugs. This is because of the limited economic payoff for pharmaceutical companies, which 
result in part from the high cost of research and clinical trials. There is little incentive to develop 
new drugs because of the drug resistance to new strains. Antibiotics are costly and time 
consuming to produce and by the time they are available to the market, there are few individuals 
to which the antibiotics will cater. Scientists are looking for drug targets that will work with 
multiple strains of TB. Third world countries are heavily affected, as they have limited resources 
to pay for drugs and have highly infected populations6. We believe that the TB Tat system is a 
target for new drug therapies.  
 
Twin Arginine Translocation Pathway 
The Tat pathway was first identified in the thylakoids of plant and was later found to be 
orthologous in gram-negative bacteria such as E. coli. The Tat pathway is said to be similar to 
the Sec pathway because they are both secretory pathways. Unlike the Sec pathway, the Tat 
protein transports folded proteins. In gram-negative bacteria, such as E. coli, the Tat system 
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usually secretes proteins to the periplasm; however in some cells, proteins can even be secreted 
extracellularly with the aid of other organelles. Also in E. coli, the Tat A proteins are said to be 
necessary for protein transport. The Tat system typically transports folded proteins, cofactors and 
virulence factors in numerous pathogens. The Tat system translocates proteins from the 
cytoplasm to the periplasm, the first step in secretion extra-cytoplasmically4. The Tat pathway is 
not found in any human cells and is known to secrete virulence factors4.  
 
E. coli is a good vector to incorporate in the MTb Tat proteins because of the similarity in amino 
acid sequence identity and similarities in shapes of the hydropathy plots. Figure 1 shows the 
amino acid sequence identities between MTb and E. coli Tat systems. The TatA, TatB, and TatC 
proteins have 29%, 32%, and 36% sequence identity, respectively. Figure 2 shows hydropathy 
plots that are similar in shape for Tat A, B and C. The similarities in amino acid positions make 
E. coli a good vector to express the MTb Tat proteins. Figure 3 shows the differences between 
the E. coli Tat system and the MTb Tat system. The order of the Tat proteins is different in E. 
coli versus in MTb. The MTb Tat proteins are controlled by two promoters, one for Tat A and 
Tat C and the other promoter controls the expression of Tat B. The MTb Tat proteins we have 
chosen to express in E. coli are controlled by two T7 promoters that can be induced with IPTG.  
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Figure 1: Amino Acid Sequences for TatA, TatB and TatC from E. coli and MTb.   
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Figure 2: Hydropathy plots for TatA, TatB and TatC from E. coli and MTb.  
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Figure 3: Gene organization of the Tat proteins in both MTb and E. coli. 
 
The Musser lab has substantial experience in the Tat transport and is ideally suited to develop an 
in vitro transport assay for the MTb Tat system. In particular, the Musser lab developed the first 
efficient in vitro Tat transport assay that uses overexpressed precursor protein. This assay has 
been used to determine the energetic requirements for transport, to characterize lipid and 
translocon-bound forms of the precursor protein, and to determine real-time interaction kinetics 
between the precursor protein and the Tat-BC receptor complex. This expertise will now be 
applied for the MTb Tat system1,6,8. 
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Objectives 
Based on work performed in Dr. Musser’s laboratory by multiple people, including myself, 
during the past summer, all three MTb Tat proteins (TatA, TatB and TatC) were expressed in E. 
coli.  We discovered that the Tat protein is partially complemented in E. coli. We consider two 
explanations for only the partial complementation: (i) The E. coli pre-SufI was not recognized by 
the MTb Tat machinery due to differences in signal peptide recognition; or (ii) MTb Tat proteins 
were not fully functional.  
  
Our goal is to build a tractable model system for in vitro biochemical study of the MTb Tat 
system. Since the MTb Tat system at least partially functionally replaces the E. coli Tat system, 
we know that it is at least partially active in E. coli. To test whether the incomplete 
complementation arises from substrate recognition (issue 1 above), we will use a model MTb Tat 
substrates BlaC and chimeric substrate plcB-BlaC, which are efficiently transported by the MTb 
Tat system9. A second explanation for the poor complementation observed thus far (issue 2), i.e., 
that the MTb Tat system is not fully functional in E. coli, is more challenging to address since 
numerous explanations are possible. The first issues we will address, if necessary, are: i) which 
of the three Tat proteins are inactive; and ii) can we increase functional incorporation by 
overexpression of E. coli SecYEG and/or YidC.  
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CHAPTER II 
METHODS 
 
Preparation of Strains.  E. coli strains CJMS2 pTB Tat ACB 28a, CJMS2 Tat ABC pET 28a, 
CJMS2 pET 28a have been described earlier (Reference 15). Overexpression cultures were 
grown in Luria-Bertani (LB) medium at 37°C supplemented with appropriate antibiotics6. Figure 
4 shows diagrams of the plasmids we constructed and used. 
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Figure 4: Plasmid Construction. 
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Creation of Inverted Membrane Vesicles (IMVs).  Creation of IMVs followed the protocol 
described earlier in reference 8. Cells were grown in LB medium overnight. E. coli strain cells 
were grown at 34°C whereas MTb strain cells were grown at 37°C. Cells were then subcultured 
and grown for around 5 hours. Cultures were then harvested by centrifugation at 4,000 g for 9 
minutes at 4°C. The pellet was then suspended in a buffer A (composed of Magnesium Sulfate, 
polyvinylpyrollidine, mannitol, DNase, RNAse, KCl, Tricine, lysozyme, EDTA, 1 mM MgSO4, 
0.5% polyvinylpyrrolidine, 450 mM mannitol, 2 mM DTT, 50 µg/ml DNase I, 10 µg/ml 
RNAase, 1 mM KCl, 100 mM Tricine, pH 7.5 with 0.4 mg/ml lysozyme, 0.5 mM EDTA, and 
protease inhibitors). This mixture was then cooled on ice for approximately 20 minutes and was 
then sedimented via centrifugation at 4,000 g for 10 minutes and resuspended in the Buffer A. 
The mixture was then passed through a French Pressure cell at high pressure to produce IMVs. 
The solution was centrifuged as explained above to remove unlysed cells and cell debris. The 
supernatant fraction was loaded over a 2.3M sucrose cushion and membranes were collected by 
ultracentrifugation at 108,000 g for 90 min at 4°C.  The IMVs collected from the interface were 
diluted with IMV dilution buffer in 1:3 dilution and then were centrifuged in an ultracentrifuged 
as described above for 30 min.  The IMV pellet was resuspended and finally stored in IMV 
storage buffer (1 mM KCl, 1 mM MgSO4, 2 mM DTT, and 10 mM HEPES, pH 7.0 with 2.2 M 
sucrose at -80°C for long-term storage in 50% glycerol)8.   
 
Light Microscopy. The morphology of E. coli stains in the absence and presence of the MTb Tat 
pathway was examined using light microscopy. The cells were viewed at a 100 X magnification 
using a Zeiss Axiovert 200 M microscope. 
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Western Blotting. The incorporation of MTb Tat proteins into the E. coli inner membrane was 
determined by Western blot analyses against MTb TatA, TatB and TatC using rabbit derived 
polyclonal antibodies. Goat polyclonal anti-rabbit IgG-HRP conjugate was used as the secondary 
antibody8. The cells were fractionated via centrifugation using ultracentrifuged at 50,000g for 10 
minutes to obtain portions of the total cell extract, cytoplasm, and inner membranes. 
 
Outer Membrane Integrity Assays. Sensitivity assays were used to determine the functional 
complementation of the E. coli Tat pathway by the MTb Tat pathway10. Sensitivity to EDTA and 
SDS were determined by culturing E. coli CJMS2 (pTB-Tat-ACB-28a) and CJMS2 (pET28a) on 
a soft agar plate in the presence of various concentrations of EDTA and SDS. Filter paper disks 
with various concentrations of EDTA and SDS were placed on the agar plate overnight.  
 
Overexpression of Tat Machinery. The Tat machinery was expressed in CJMS2 (pTB-Tat-
ACB-28a) in LB media with various concentrations of IPTG for a 5-hour growth period. 
Samples were then collected (1 ml/OD) and centrifuged for 4 minutes at 9,000 g. A Western blot 
was performed using the samples against MTb TatA and TatB antibodies. An IPTG induction 
time course was then performed by inducing strain with 100 µM IPTG. Samples were taken at 
one-hour increments for 9 hours (1 mL/OD). A Western blot was performed using the samples 
against MTb Tat A and Tat B antibodies. 
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In vivo Transport of B-lactamase. This sensitivity assay was performed in a similar manner to 
the EDTA and SDS sensitivity assays however we used the plasmids pPlcB-BlaC and pBlaC in a 
compatible plasmid. The E. coli CJMS2 (ΔTatABCDE) was used as a host while doing this 
assay. Disks are dipped in various concentrations of Ampicillin and grown on a lawn of E. coli 
culture. Cells are then grown at 37°C overnight.  
 
pre-SufI Binding Assay. The concentration of bound E. coli authentic Tat precursor pre-SufI 
(fluorescently labeled to Atto 565 dye) to E. coli and MTb Tat machinery were determined by 
performing a binding assay using IMVs. Standard in vitro translocation assays used a 35-µl 
reaction volume containing 50 nM pre-SufI and 4 mM NADH in Translocation Buffer (TB; 5 
mM MgCl2, 50 mM KCl, 200 mM sucrose, 57 µg/ml BSA, 25 mM MOPS, and 25 mM MES, 
pH 7.0). Solutions were prewarmed at 37°C for 5 min before the addition of IMVs (to a typical 
final concentration of A280 = 5). After a 30 min incubation at 37°C, reactions were quenched in 
an ice bath for 2 min. Samples were digested with 0.73 mg/ml proteinase K for 40 min at RT. 
Digestions were quenched with 68 mM PMSF, diluted twofold with 2× Gel Buffer (4% SDS, 
10% glycerol, 0.04% bromophenol blue, 0.4% β-mercaptoethanol, 10 M urea, and 200 mM Tris, 
pH 6.8), and incubated in a boiling water bath for 10 min. Samples were centrifuged briefly at 
16,000 g, and then were resolved by 8% SDS-PAGE with known standards. Gels were 
electroblotted onto PVDF membranes and immunoblotted with SufI antibodies and examined 
using a Bio-Rad phosphorimager12. 
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CHAPTER III 
RESULTS 
 
Project Design.  The first series of experiments performed was to see if the Tat system was 
functional in the E. coli vector. We performed a microscopy to show the role of the Tat proteins 
in the growth and cell division of the CJMS2 strain. We then progressed where the Tat proteins 
were located within E. coli and then progressed to show the role of Tat proteins in maintaining 
the cell wall integrity. We finally progressed to the most important issue, which is to find out if 
two authentic MTb Tat precursors BlaC and PlcB-BlaC can be efficiently transported by the 
MTb Tat pathway expressed in E. coli. 
 
Role of Tat Protein Incorporation within Inner Membrane. Tat machinery is imperative for 
the growth and development of cells1. As shown in Figure 5, in the absence of Tat machinery, 
cells grown are long, thin, unhealthy and not well divided. In the presence of Tat machinery, 
cells are well divided and appear healthier. This shows that Tat machinery is essential for the 
growth and development of bacteria. 
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Figure 5. Complementation of the E. coli Tat machinery by the MTb Tat pathway. 
 
 
Incorporation of Tat Proteins in the Inner Membrane: Cellular fractionation indicates that 
the MTb Tat proteins are incorporated into the inner membrane. Figure 6A shows the results 
obtained during the summer of 2013 and 6B shows the results obtained during the spring of 
2014. Figure 6B shows that Tat A and B were localized in the cytoplasm whereas Tat C was 
found in the inner membrane. This contradicts what was found previously. Further studies must 
be performed for conclusive results.  
 
 
 
 
 
 
 
 E. coli CJMS2 (pET 28a) E. coli CJMS2 (pTB-TatACB-28a) 
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EDTA SDS Sensitivity Assay: Some of the amodases transported by the Tat system, AMIA and 
AMIC, are involved in cell wall maintenance14.  Thus, Tat deficient strains have higher cell 
envelope permeability13, and thus are more susceptible to chemical reagents such as EDTA and 
SDS. Figure 7 shows that in the presence of Tat Machinery, colonies are formed in moderate 
amounts of EDTA; however, in the absence of Tat machinery, colonies are not formed. Figure 8 
shows that in large concentrations of EDTA and SDS, colonies cannot be formed, regardless of 
the presence of Tat machinery. This experiment was successful in showing that the MTb Tat 
machinery was at least partially functionally in E. coli because of the growth of colonies in the 
presence of ampicillin. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: EDTA Sensitivity Assay 
Tat - Tat + 
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IPTG Induction of Tat Machinery. The T7 promoter controls the Tat proteins incorporated 
into E. coli. IPTG can induce the T7 promoter, which allows that translocation of Beta 
Lactamase translocation across the inner membrane. As seen in Figure 9, a high concentration of 
IPTG causes the strain to not divide as well and inhibits growth rather than optimize it. The 
colony forming units are indicative of cell growth in the presence of IPTG.  A western blot 
analysis determined that the minimum concentration of IPTG required for induction is 100 µM. 
A western blot analysis also determined that strains must be grown at least 4-5 hours for ideal 
concentration of cell growth (Figure 10).  
 
 
Figure 8: Effect of SDS and EDTA on Growth 
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PreSufI Binding Assay. We have performed experiments to see if the E. coli Tat authentic 
precursor preSufI could be translocated across the membrane. We found that preSufI was better 
transported with authentic E. coli Tat machinery rather than the MTb Tat machinery (Figure 11). 
For this reason, we have decided to repeat the assay with purified BlaC protein, which is 
authentic to the MTb Tat system.  
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CHAPTER IV 
CONCLUSIONS AND DISCUSSION 
 
The purpose of this experiment was to develop a tractable model organism in which we can 
characterize the MTb Tat system. The Tat machinery is essential for bacterial cell growth and 
development. Since we have previously discovered the MTb Tat system to partially function in 
E. coli, we have tried to develop a fully functional and complementary model. After discovering 
that the MTb Tat machinery was successfully expressed into E. coli, we determined the ideal 
concentration and time period for IPTG induction of the T7 promoter so that the Beta lactamase 
can be secreted into the inner membrane. In the presence of BlaC and Tat machinery, the cell 
becomes resistant to antibiotics such as ampicillin. This is imperative in showing that the Tat 
machine is functional after having been incorporated into E. coli.  
 
Currently we are working on growing strains that will transport BlaC and show resistance to 
ampicillin. This assay is performed in a manner similar to the EDTA and SDS sensitivity assays. 
Future plans of the lab include creating strains that incorporate both E. coli and TB Tat proteins 
to see if any of the TB Tat proteins is not functional in E. coli. We are also currently purifying 
the BlaC precursor so that we can use it for binding and protein transport assays. 
 
The CJMS2 strain we are working with can sometimes be problematic. Although the CJMS2 
strain has an IPTG inducible T7 promoter sequence, we are having trouble in testing function of 
the MTb Tat proteins when incorporated. For this reason, we will try to clone the MTb Tat 
proteins in the MC4100 wild type strain. This strain will have an arabinose induced promoter 
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sequence. The MTb Tat proteins will be arranged in a similar manner to the E. coli Tat proteins 
to hopefully yield a more successful transport assay.  
 
Creating a functional assay will serve as a target for drug testing. Inhibiting the TB Tat 
machinery will stop the growth and development of these cells. As the strains of tuberculosis 
become increasingly pathogenic, it is imperative that scientists for the drugs that are currently on 
the market. The TB Tat machinery serves as a potentially successful drug target.  
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